Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody aims to tame rare brain disorder

NCT ID NCT04658199

Ongoing Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests the long-term safety of an experimental drug called UCB0107 (bepranemab) in people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Participants who completed a prior study receive regular infusions of the drug. The main goal is to see if long-term use is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental antibody drug called UCB0107 (bepranemab)
What this could lead to
If successful, this could pave the way for a treatment that slows the progression of progressive supranuclear palsy.
What could go wrong
This is a small, early-phase study focused on safety, not effectiveness. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE SUPRANUCLEAR PALSY

Contacts and locations

Locations

  • Psp002 40002

    Leuven, Belgium

  • Psp002 40024

    Hanover, Germany

  • Psp002 40100

    Madrid, Spain

  • Psp002 40122

    Edegem, Belgium

  • Psp002 40165

    Southampton, United Kingdom

  • Psp002 40175

    London, United Kingdom

  • Psp002 40267

    Barcelona, Spain

  • Psp002 40268

    Pamplona, Spain

  • Psp002 40276

    Düsseldorf, Germany

  • Psp002 40277

    Bochum, Germany

  • Psp002 40278

    Essen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.